Details for New Drug Application (NDA): 050675
✉ Email this page to a colleague
NDA 050675 describes VANTIN, which is a drug marketed by Pfizer and is included in two NDAs. Additional details are available on the VANTIN profile page.
The generic ingredient in VANTIN is cefpodoxime proxetil. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefpodoxime proxetil profile page.
The generic ingredient in VANTIN is cefpodoxime proxetil. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefpodoxime proxetil profile page.
Summary for 050675
| Tradename: | VANTIN |
| Applicant: | Pfizer |
| Ingredient: | cefpodoxime proxetil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 50MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 7, 1992 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 100MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 7, 1992 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
